Believe it or not, it’s that time of year to start thinking about making the most out of your JP Morgan 2018 experience. Given what we know and have come to anticipate, each year investors and partners expect to see various (and promising) regulatory milestones achieved, and in the past three years all eyes have been on ORPHANS. Attaining an orphan drug designation or a rare pediatric disease designation, or having taken your orphan therapy through a pre-IND meeting gaining an understanding of agency expectations and a clear path forward makes a difference when interacting with potential partners.
Read the full content at the original LinkedIn post.
Sabrina Mogle
CEO | Regulatory Strategist | Orphan Product Advisor
